Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Small orphan drug firms caught by Germany's AMNOG assessments

This article was originally published in Scrip

Executive Summary

Small companies with orphan drug products whose turnover is less than €50 million are not excluded from cost-effectiveness assessments introduced this year under Germany’s healthcare reform act, said Dr Alexander Natz, Brussels representative for the BPI, the German association for mid-sized pharma companies. In an interview with Scrip, he warned companies not to be complacent






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts